Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations
The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an e...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2010-09-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/1191 |
| _version_ | 1811194081802452992 |
|---|---|
| author | C Taverna M Bargetzi D Betticher J Gmür M Gregor U Hess N Ketterer E Lerch T Matthes U Mey T Pabst C Renner |
| author_facet | C Taverna M Bargetzi D Betticher J Gmür M Gregor U Hess N Ketterer E Lerch T Matthes U Mey T Pabst C Renner |
| author_sort | C Taverna |
| collection | DOAJ |
| description |
The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma.
|
| first_indexed | 2024-04-12T00:20:10Z |
| format | Article |
| id | doaj.art-5720a28143ee47f8b2e120a562ef7699 |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-12T00:20:10Z |
| publishDate | 2010-09-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-5720a28143ee47f8b2e120a562ef76992022-12-22T03:55:44ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972010-09-01140373810.4414/smw.2010.13054Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendationsC TavernaM BargetziD BetticherJ GmürM GregorU HessN KettererE LerchT MatthesU MeyT PabstC Renner The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma. https://www.smw.ch/index.php/smw/article/view/1191bone marrow transplantBortezomibelderlylenalidomidemultiple myelomarelapsed/refractory |
| spellingShingle | C Taverna M Bargetzi D Betticher J Gmür M Gregor U Hess N Ketterer E Lerch T Matthes U Mey T Pabst C Renner Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations Swiss Medical Weekly bone marrow transplant Bortezomib elderly lenalidomide multiple myeloma relapsed/refractory |
| title | Integrating novel agents into multiple myeloma
treatment – current status in Switzerland
and treatment recommendations |
| title_full | Integrating novel agents into multiple myeloma
treatment – current status in Switzerland
and treatment recommendations |
| title_fullStr | Integrating novel agents into multiple myeloma
treatment – current status in Switzerland
and treatment recommendations |
| title_full_unstemmed | Integrating novel agents into multiple myeloma
treatment – current status in Switzerland
and treatment recommendations |
| title_short | Integrating novel agents into multiple myeloma
treatment – current status in Switzerland
and treatment recommendations |
| title_sort | integrating novel agents into multiple myeloma treatment current status in switzerland and treatment recommendations |
| topic | bone marrow transplant Bortezomib elderly lenalidomide multiple myeloma relapsed/refractory |
| url | https://www.smw.ch/index.php/smw/article/view/1191 |
| work_keys_str_mv | AT ctaverna integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT mbargetzi integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT dbetticher integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT jgmur integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT mgregor integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT uhess integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT nketterer integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT elerch integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT tmatthes integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT umey integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT tpabst integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations AT crenner integratingnovelagentsintomultiplemyelomatreatmentcurrentstatusinswitzerlandandtreatmentrecommendations |